185 related articles for article (PubMed ID: 33287758)
21. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
Parmar MK; Ledermann JA; Colombo N; du Bois A; Delaloye JF; Kristensen GB; Wheeler S; Swart AM; Qian W; Torri V; Floriani I; Jayson G; Lamont A; Tropé C;
Lancet; 2003 Jun; 361(9375):2099-106. PubMed ID: 12826431
[TBL] [Abstract][Full Text] [Related]
23. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
24. The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer.
Rocconi RP; Matthews KS; Kemper MK; Hoskins KE; Huh WK; Straughn JM
Gynecol Oncol; 2009 Aug; 114(2):242-5. PubMed ID: 19447480
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
26. Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy.
Chiyoda T; Tsuda H; Nomura H; Kataoka F; Tominaga E; Suzuki A; Susumu N; Aoki D
Eur J Gynaecol Oncol; 2010; 31(4):364-8. PubMed ID: 20882873
[TBL] [Abstract][Full Text] [Related]
27. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
28. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
29. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C
Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114
[TBL] [Abstract][Full Text] [Related]
30. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
31. Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival.
Mardas M; Stelmach-Mardas M; Madry R
Support Care Cancer; 2017 Mar; 25(3):795-800. PubMed ID: 27771784
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.
Stiff PJ; Bayer R; Kerger C; Potkul RK; Malhotra D; Peace DJ; Smith D; Fisher SG
J Clin Oncol; 1997 Apr; 15(4):1309-17. PubMed ID: 9193322
[TBL] [Abstract][Full Text] [Related]
33. Effect of increased number of neoadjuvant chemotherapy cycles on tumor resectability and pathologic response in advanced stage epithelial ovarian cancer.
Akilli H; Rahatli S; Tohma YA; Karakas LA; Altundag O; Ayhan A
J BUON; 2018 Dec; 23(7):111-115. PubMed ID: 30722119
[TBL] [Abstract][Full Text] [Related]
34. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
35. The changes in residual cancer burden after interval debulking surgery are effective in evaluating the response to adjuvant chemotherapy.
Kong L; Li X; Xu Q; Wei L; Wang J; Cui H; Wang S; Zhao Y
Chemotherapy; 2011; 57(3):209-16. PubMed ID: 21555882
[TBL] [Abstract][Full Text] [Related]
36. Maintenance Chemotherapy in Patients with Platinum-Sensitive Relapsed Epithelial Ovarian Cancer after Second-Line Chemotherapy.
Chen YF; Hsu ST; Hwang SF; Sun L; Liu CK; Shih YH; Lu TF; Wang JS; Lu CH
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256699
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Trillsch F; Mahner S; Hilpert F; Davies L; García-Martínez E; Kristensen G; Savarese A; Vuylsteke P; Los M; Zagouri F; Gladieff L; Sehouli J; Khoon Lee C; Gebski V; Pujade-Lauraine E
Ann Oncol; 2016 Sep; 27(9):1733-9. PubMed ID: 27287207
[TBL] [Abstract][Full Text] [Related]
39. Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
Dockery LE; Rubenstein AR; Ding K; Mashburn SG; Burkett WC; Davis AM; Doo DW; Arend RC; Moore KN; Gunderson CC
Gynecol Oncol; 2019 Nov; 155(2):201-206. PubMed ID: 31522837
[TBL] [Abstract][Full Text] [Related]
40. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]